Recombinant multivalent malarial vaccine against plasmodium falciparum
CA 2337754 C · Owner: The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services · Inventors: Lal, Altaf A.; Hasnain, Seyed E.; Shi, Ya Ping
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A recombinant protein is provided which comprises peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum. The protein is useful as a reagent and, when combined with a pharmaceuticallyacceptable vehicle or carrier, is useful as a vaccine against the malarial parasite Plasmodium falciparum. A genetic construct used to produce this recombinant protein vaccine is also described. In addition antibodies to this , recombinant protein are provided which are useful for the detection and measurement of peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 19, 1999 and granted May 24, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 19, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 19, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.